Fig. 1: The clinicopathological data of 28 MIBC patients who received cisplatin-based NAC. | Cell Death & Disease

Fig. 1: The clinicopathological data of 28 MIBC patients who received cisplatin-based NAC.

From: Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1/ERβ/Bcl-2 signalling

Fig. 1

a, b The expression of α-SMA (a) and ERβ (b) in adjacent normal bladder, pretreatment biopsy and resected RC samples (α-SMA ×200, ERβ ×100). c α-SMA (left) and ERβ (right) scores in the adjacent normal bladder with or without NAC treatment and in the pretreatment biopsy and resected RC specimens with different pathological outcomes. d The correlation of α-SMA expression in the cancer-associated stroma and BCa ERβ expression in the pretreatment biopsy tissues (left) and RC (right) tissues. e, f Kaplan–Meier survival curves of OS (e) and PFS (f) in the 28 patients. The results indicated that α-SMA and ERβ expression was related to OS and PFS. Data are presented as the mean ± SD. *P < 0.05

Back to article page